Alder BioPharmaceuticals (ALDR) : Investors lapped up stocks on upticks to the tune of $1.28 million in the Mondays trading session. The trading value on downticks was comparatively at $0.56 million and the uptick to downtick ratio of 2.28 indicates continuous buying by the bulls. The net money flow into the stock was $0.72 million. Upticks saw transactions worth $0.72 clearly indicating buying by large investors. The total money flow for block trades stood at $0.72 million, which is a positive for the stock in the long-term. Alder BioPharmaceuticals (ALDR) fell $0.14 during the day at $30.99, a drop of -0.45% over the previous days close. However, for the week, the stock is -1.46%, compared to the previous week.
Shares of Alder Biopharmaceuticals Inc. rose by 2.7% in the last five trading days and 20.76% for the last 4 weeks. Alder Biopharmaceuticals Inc. is up 22.61% in the last 3-month period. Year-to-Date the stock performance stands at -5.42%.
Alder BioPharmaceuticals (NASDAQ:ALDR): During Mondays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $31.36 and $30.69 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $31.52. The buying momentum continued till the end and the stock did not give up its gains. It closed at $31.24, notching a gain of 0.35% for the day. The total traded volume was 352,210 . The stock had closed at $31.13 on the previous day.
In a related news,The director officer (President and CEO) of Alder Biopharmaceuticals Inc, Schatzman Randall C sold 10,000 shares at $31.67 on August 1, 2016. The Insider selling transaction had a total value worth of $316,700. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Alder Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy, as well as speed of onset and durability of therapeutic response. The Companys pipeline includes ALD403, Clazakizumab and ALD1613. ALD403 is the Companys monoclonal antibody targeted to calcitonin gene-related peptide (CGRP) for migraine prevention. Clazakizumab is a monoclonal antibody that inhibits the pro-inflammatory cytokine interleukin-6 (IL-6), and is in development for both rheumatoid arthritis (RA) and psoriatic arthritis (PsA). ALD1613 is a monoclonal antibody that inhibits Adrenocorticotropic Hormone (ACTH), and is being developed for the treatment of Cushings disease.